OBJECTIVE: The aim of the present study was to investigate the relationship between the changes in lean and fat mass during gonadotropin-releasing hormone agonist (GnRH agonist) therapy. METHODS: Subjects were 24 premenopausal women (mean age, 39.5+/-9.4 years; range, 32-52 years) with uterine leiomyomas. They were given GnRH agonist (leuprorelin acetate, 3.75 mg) monthly for 4 months. Age and height were recorded. Body weight, regional and total body composition, and the ratio of trunk fat mass to leg fat mass (trunk-leg fat ratio) were assessed by whole body scanning with dual-energy X-ray absorptiometry. Changes in these variables were investigated. Relationships between the changes in regional lean and fat mass were investigated using Pearson's correlation test. RESULTS: Trunk fat mass significantly increased from 8616+/-3538 to 9265+/-3526 g (P<0.01) and trunk-leg fat ratio significantly increased (1.02+/-0.39 to 1.07+/-0.39, P<0.05). Trunk lean mass significantly decreased from 18,509+/-2602 to 17,916+/-2402 g (P<0.01). However, body weight, and lean and fat mass component in the extremities did not change. Change in trunk fat mass was inversely correlated with change in trunk lean mass (r=-0.439, P<0.05), but such relationships were not observed in arm and leg regions. CONCLUSION: Inverse relationship between the changes in trunk lean and fat mass is observed during GnRH agonist therapy.
OBJECTIVE: The aim of the present study was to investigate the relationship between the changes in lean and fat mass during gonadotropin-releasing hormone agonist (GnRH agonist) therapy. METHODS: Subjects were 24 premenopausal women (mean age, 39.5+/-9.4 years; range, 32-52 years) with uterine leiomyomas. They were given GnRH agonist (leuprorelin acetate, 3.75 mg) monthly for 4 months. Age and height were recorded. Body weight, regional and total body composition, and the ratio of trunk fat mass to leg fat mass (trunk-leg fat ratio) were assessed by whole body scanning with dual-energy X-ray absorptiometry. Changes in these variables were investigated. Relationships between the changes in regional lean and fat mass were investigated using Pearson's correlation test. RESULTS: Trunk fat mass significantly increased from 8616+/-3538 to 9265+/-3526 g (P<0.01) and trunk-leg fat ratio significantly increased (1.02+/-0.39 to 1.07+/-0.39, P<0.05). Trunk lean mass significantly decreased from 18,509+/-2602 to 17,916+/-2402 g (P<0.01). However, body weight, and lean and fat mass component in the extremities did not change. Change in trunk fat mass was inversely correlated with change in trunk lean mass (r=-0.439, P<0.05), but such relationships were not observed in arm and leg regions. CONCLUSION: Inverse relationship between the changes in trunk lean and fat mass is observed during GnRH agonist therapy.
Authors: Edward L Melanson; Kathleen M Gavin; Karen L Shea; Pamela Wolfe; Margaret E Wierman; Robert S Schwartz; Wendy M Kohrt Journal: J Appl Physiol (1985) Date: 2015-09-03
Authors: Rachael E Van Pelt; Wendolyn S Gozansky; Robert C Hickner; Robert S Schwartz; Wendy M Kohrt Journal: Obesity (Silver Spring) Date: 2006-12 Impact factor: 5.002
Authors: Karen L Shea; Kathleen M Gavin; Edward L Melanson; Ellie Gibbons; Anne Stavros; Pamela Wolfe; John M Kittelson; Sheryl F Vondracek; Robert S Schwartz; Margaret E Wierman; Wendy M Kohrt Journal: Menopause Date: 2015-10 Impact factor: 2.953
Authors: Edward L Melanson; Kate Lyden; Ellie Gibbons; Kathleen M Gavin; Pamela Wolfe; Margaret E Wierman; Robert S Schwartz; Wendy M Kohrt Journal: Med Sci Sports Exerc Date: 2018-08 Impact factor: 5.411
Authors: Kara L Marlatt; Dori R Pitynski-Miller; Kathleen M Gavin; Kerrie L Moreau; Edward L Melanson; Nanette Santoro; Wendy M Kohrt Journal: Obesity (Silver Spring) Date: 2022-01 Impact factor: 5.002
Authors: Kathleen M Gavin; Edward L Melanson; Kerry L Hildreth; Ellie Gibbons; Daniel H Bessesen; Wendy M Kohrt Journal: Obesity (Silver Spring) Date: 2020-11 Impact factor: 5.002